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Abstract
Introduction: The use of glutamine as a dietary supplement is associated with a reduced risk of infection. We
hypothesized that the underlying mechanism could be an increase in the expression and/or functionality of
Toll-like receptors (TLR), key receptors sensing infections. The objective of this study was to evaluate whether
glutamine supplementation alters the expression and functionality of TLR2 and TLR4 in circulating monocytes of
trauma patients admitted to the intensive care unit (ICU).
Methods: We designed a prospective, randomized and single-blind study. Twenty-three patients received
parenteral nutrition (TPN) with a daily glutamine supplement of 0.35 g/kg. The control group (20 patients) received
an isocaloric-isonitrogenated TPN. Blood samples were extracted before treatment, at 6 and 14 days. Expression of
TLR2 and TLR4 was determined by flow cytometry. Monocytes were stimulated with TLR specific agonists and
cytokines were measured in cell culture supernatants. Phagocytic ability of monocytes was also determined.
Results: Basal characteristics were similar in both groups. Monocytes from patients treated with glutamine
expressed the same TLR2 levels as controls before treatment (4.9 ± 3.5 rmfi vs. 4.3 ± 1.9 rmfi, respectively; P = 0.9),
at Day 6 (3.8 ± 2.3 rmfi vs. 4.0 ± 1.7 rmfi, respectively; P = 0.7) and at Day 14 (4.1 ± 2.1 rfim vs. 4.6 ± 1.9 rmfi,
respectively; P = 0.08). TLR4 levels were not significantly different between the groups before treatment:
(1.1 ± 1 rmfi vs 0.9 ± 0.1 rmfi respectively; P = 0.9), at Day 6 (1.1 ± 1 rmfi vs. 0.7 ± 0.4 rmfi respectively; P = 0.1)
and at Day 14 (1.4 ± 1.9 rmfi vs. 1.0 ± 0.6 rmfi respectively; P = 0.8). No differences in cell responses to TLR
agonists were found between groups. TLR functionality studied by phagocytosis did not vary between groups.
Conclusions: In trauma patients in the intensive care unit, TPN supplemented with glutamine does not improve
the expression or the functionality of TLRs in peripheral blood monocytes.
Trial registration: ClinicalTrials.gov Identifier: NCT01250080.
Introduction
Glutamine is the most abundant nonessential amino
acid in the human body. Besides its role as a constituent
of proteins and its importance in amino acid transami-
nation, glutamine may modulate immune cells [1].
Thus, glutamine deprivation reduces proliferation of
lymphocytes, influences expression of surface activation
markers of lymphocytes and monocytes, affects the
production of cytokines, and stimulates apoptosis [1]. In
addition, glutamine influences a variety of different
molecular pathways. For example, glutamine stimulates
the formation of heat shock protein 70 in monocytes by
enhancing the stability of mRNA [2,3], influences the
redox potential of the cell by enhancing the formation
of glutathione [4,5], induces cellular anaerobic effects by
increasing the cell volume [6,7], activates mitogen-acti-
vated protein kinases [8], and interacts with particular
aminoacyl-transfer RNA synthetases in specific gluta-
mine-sensing metabolism [2].
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defence against pathogens and targets structurally con-
served molecules, the so-called pathogen-associated
molecular patterns (PAMPs) [9,10]. Innate responses
are in most cases sufficient to eliminate invading
microbes. Mammalian Toll-like receptors (TLR) com-
prise a family of germ line-encoded trans-membrane
receptors which recognize PAMPs [9-11]. Activation of
TLRs leads to the induction of inflammatory responses,
phagocytosis but also to the development of antigen
specific adaptive immunity [10]. Among this family of
receptors, TLR2 and TLR4 have received great atten-
tion. TLR4 is essential for the recognition of lipopoly-
saccharide (LPS), a major component of Gram-negative
bacteria, whereas TLR2 recognizes a large number of
ligands including bacterial lipoteichoid acid and
lipoproteins.
W ea n do t h e r s[ 1 2 - 1 5 ]h a v es h o w nt h a tt r a u m a
patients present a dysregulation of the innate immune
system, namely reduced expression of TLRs and
blunted response to specific agonists markedly to LPS.
Moreover, we have also shown that monocytes from
trauma patients phagocytosized less efficiently than
monocytes from control subjects [12]. On the other
hand, clinical studies have shown that glutamine, as a
dietary supplement for patients in critical condition,
decreases the incidence of infection, primarily pneumo-
nia, bacteremia, and sepsis [16,17]. It has been postu-
lated, though not formally proven yet, that glutamine’s
beneficial effect could be due to a positive effect on the
innate immune system. Given the importance of TLRs
and TLRs-dependent signalling in host defence against
infections we hypothesized that glutamine may increase
the expression and/or functionality of TLRs, which in
turn may have beneficial effects to clear infections. In a
pilot report, in a general population of critical care
patients, glutamine used as a dietary supplement did
not increase the expression of TLR2 or TLR4 [18]. In
this second report we have evaluated whether gluta-
mine dietary supplement may affect not only the
expression of TLR2 and TLR4 but also their function-
ality in circulating monocytes from peripheral blood
in a specific group of trauma patients admitted to
the ICU.
Materials and methods
This prospective and comparative study took place at
Son Dureta University Hospital (Palma de Mallorca,
Spain), and was approved by the Ethics Committee of
the Balearic Islands on 31 January 2007.
In all cases, informed consent for inclusion in the
study was sought from the patient or the closest family
member if the patient was unconscious.
Study design
We designed a randomized, single blind, prospective
study, with comparative therapeutic intervention with
two groups: trauma patients treated with TPN supple-
mented with glutamine and those receiving TPN with-
out glutamine.
Random selection was based on a computer-generated
list that assigned patients to groups consecutively. Those
who processed samples in the research unit did not know
whether the patient had received glutamine or not.
Patients and interventions
Trauma patients admitted to the intensive care unit
(ICU) at a university third level hospital between 18 and
75 years (inclusive) with moderate to severe trauma, as
defined by an Injury Severity Score (ISS) > 12 points
were included in the study. Exclusion criteria were:
patients who were under 17 and over 76 years of age,
patients whose life expectancy was less than five days,
who were allergic to glutamine, whose basic pathology
included any serious immune system condition (dia-
betes, HIV, lupus, and so on) or who, in their long-term
treatment prior to admission to ICU, received corticoids
or any other immunosuppressant medication. A negative
pregnancy test was required before women of childbear-
ing age could be included in the study.
All patients received standardized advanced trauma
life support (ATLS)-adapted emergency department
treatment and standardized intensive care unit therapy.
All patients who were admitted to the ICU and
received TPN as part of their treatment were selected
for inclusion in the study. Indications for TPN treat-
ment were based on the guidelines of the American
Society of Parenteral and Enteral Nutrition (ASPEN)
[19]. The indications for TPN were: contraindication for
enteral nutrition (mainly abdominal surgery or abdom-
inal trauma) or failure in achieve nutritional goals with
enteral nutrition.
Of 43 consecutive patients who met the inclusion cri-
teria, 23 were randomly assigned to receive a daily gluta-
mine supplement of 0.35 g/kg weight as N2-L-Alanyl-L-
Glutamine (0.5 g/kg/d - Dipeptiven Fresenius Kabi
España) during five days. The treatment period of five
days was chosen according to other clinical studies
[16,20,21]. Basic TPN support for both groups was iden-
tical: StructoKabiven (Fresenius Kabi España), with a
c a l o r i ci n t a k eo f2 8k c a lk g
-1 d
-1 and the following dis-
tribution of macronutrients: 0.28 g kg
-1 d
-1 of nitrogen,
3.5 g kg
-1 d
-1 of glucose and 1.08 g kg
-1 d
-1 of lipids, in
addition to standard vitamins and trace elements. The
control group (n = 20 patients) received a supplemental
volume of the basic TPN solution to achieve an isocalo-
ric and isonitrogenated formula with the study group.
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with glutamine was finished after the fifth day, was
based on clinical data and was decided by the clinician
responsible for the patient.
Besides our previous study [18] screening the litera-
ture, we found no previous studies identifying a correla-
tion between TLR and glutamine in humans. Therefore,
it was determined that a sample size of 40 patients
would be sufficient for this study.
In both groups, the peripheral blood samples for the
study of TLRs in monocytes were extracted before begin-
ning treatment (basal sample), at the end of the gluta-
mine supplement (Day 6), and at 14 days ± 24 hours
after initiating treatment.
T h e s et i m ep o i n t sw e r ec h o s e nb e c a u s et h em e d i a n
length of stay of the trauma patients in our ICU is 10
days, which is in accordance with the data obtained
from the ENVIN-HELICS study in Spain [22].
Because of the small volume of blood collected we
could not perform all the analysis for each patient and,
therefore, the phagocytosis assays were performed only
for a small group of them. However, patients were not
selected and were included consecutively as the different
parts of the study were performed. The patients enrolled
in the different sets of assays were homogenous in terms
of severity and age.
Data collection
Epidemiological data were collected, including date and
time of sample extraction, description of the event that
motivated ICU admission (diagnosis and severity scores),
comorbidities of each patient and the appearance of any
complications during ICU stay including total days of
mechanical ventilation, ICU and hospital length of stay.
Among the data collected there were all the treat-
ments that patients received during their ICU stay, espe-
cially all pharmacological treatments with known anti-
inflammatory properties that could affect the study
results. All members of both of the two patient groups
were handled and treated equivalently.
With respect to infections, samples were analyzed
whenever there was a clinical suspicion of possible
infection [23]. The definition of nosocomial infection
used in this study is that proposed by the CDC [24] and
it was mainly based on microbiological findings. Blood
and other cultures were done at our institution follow-
ing standard microbiological procedures, including incu-
bation in anaerobic atmosphere when applicable [25].
Flow cytometry
Expression of TLR2 and TLR4 in peripheral blood mono-
cytes was determined by flow cytometry. Blood samples
(one sample per patient) were collected in a K2-anticoa-
gulation medium. It is known that this medium does not
affect the expression of TLR2 and TLR4 [26]. A total of
100 μL was incubated with a combination of anti-CD14
fluorescein conjugated (clone My4, 10 μg/mL; Beckman
Coulter, Brea, California, USA) and anti-TLR2 (clone
TL2.1, 10 μg/mL; ebioscience, San Diego, California,
USA) or anti-TLR4 (clone HTA125, 10 μg/mL;
ebioscience, San Diego, California, USA) phycoerythrin
conjugated in the presence of 25 μL of fetal calf serum
during 30 minutes at 4°C. A total of 2 ml of FACS lysing
solution (Beckton Dickinson, Franklin Lakes, New Jersey,
USA) was added to the samples which were incubated 10
minutes at room temperature. Samples were centrifuged
in a clinical centrifuge (530 ×g , 5 minutes, 25°C) and the
cellular pellet was washed once with 1% BSA-0.1%
sodium azide in PBS. Finally cells were resuspended in
500 μl IsoFlowTM Sheath Fluid (Beckman Coulter). The
analyses were carried out in an Epics XL flow cytometer
using the Expo32 software (Beckman Coulter, Brea, Cali-
fornia, USA). Monocytes were identified by gating on a
side versus CD14 dot plot. The levels of TLR2 and TLR4
were expressed as relative mean fluorescence intensity
(rmfi). The non-specific binding was corrected by sub-
traction of mfi values corresponding to isotype matched
antibodies. A total of 10,000 monocytes were analysed in
every experiment.
Monocyte isolation and stimulation
Blood samples collected in 3.8% sodium citrate tubes,
were diluted 1:5 in RPMI-1640 supplemented with 10%
heat inactivated Fetal Calf Serum (FCS), glutamine (2
mM), HEPES (200 mM) and antibiotics (penicillin-strep-
tomycin) and monocytes were obtained using a com-
mercial isolation kit exactly as recommended by the
manufacturer (Dynal monocyte negative isolation kit,
Oxoid, Cambridge, United Kingdom). This collection
method does not affect TLR-ligand induced cytokine
response [26]. Lymphocytes represent less than 5% of
the cells after this procedure. Cell viability was assessed
by trypan blue dye exclusion and was > 95%. Cells were
finally resuspended at a cell density of 10
6 cells/ml in
RPMI-1640 medium supplemented with 10% heat inac-
tivated FCS, glutamine (2 mM), HEPES (200 mM) and
antibiotics (penicillin-streptomycin). Cells were cultured
in 96-well plates at a cell density of 10
5 per well. Cells
were stimulated with different amounts of purified LPS
from Escherichia coli O111:B4 (Sigma Chemicals, Saint
Louis, Missouri, USA), Pam3CSK4 (PAM; Invivogen,
San Diego, California, USA) or zymosan (Invivogen).
LPS was repurified exactly as previously described [27].
This procedure results in LPS preparations that utilize
TLR4, and not TLR2, for signalling. After 16 hours cell
culture supernatants were collected, cell debris was
removed by centrifugation, and samples were frozen at
-80°C until assayed.
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We determined the concentration of IL-1b,I L - 6 ,T N F a
and IL-10 in cell culture supernatants using a bead
array ELISA according to the instructions of the manu-
facturer (CBA Kit, BD Biosciences, Franklin Lakes, New
Jersey, USA). The assay sensitivity for each cytokine was
7.2 pg/mL for IL-1b, 2.5 pg/mL for IL-6, 3.7 pg/mL for
TNFa and 3.3 pg/mL for IL-10.
Phagocytosis
To determine the phagocytic capability of monocytes, the
assay described by Blander et al. was performed [28].
Briefly, live Escherichia coli expressing green fluorescent
protein was added to 100 μL of whole blood collected in
K2-anticoagulation medium tubes. Bacteria were added at
a ratio of 100 bacteria per monocyte. After 30-minutes
incubation at 37°C, samples were centrifuged in a clinical
centrifuge (530 ×g , 5 minutes, 25°C) and the cellular pel-
let was washed once with 1% BSA-0.1% sodium azide in
PBS. Finally cells were resuspended in 1 mL IsoFlowTM
Sheath Fluid (Beckman Coulter). The analyses were car-
ried out in an Epics XL flow cytometer using the Expo32
software. Monocytes were identified by gating on a side
versus CD14 dot plot and GFP fluorescence recorded.
Results were expressed as relative mean fluorescence
intensity (rmfi) measured in arbitrary units after substrac-
tion of mfi values corresponding to monocytes labeled
with CD14 antibody. A total of 10,000 monocytes were
analysed in every experiment. Phagocytosis was per-
formed in serum-free media to eliminate contributions of
Fc and/or complement receptors.
Statistical analysis
The quantitative variables are expressed as the mean
and standard deviation (SD) or as the median and inter-
quartiles. Qualitative variables are expressed as percen-
tages, with a confidence interval of 95% (CI 95%). To
determine whether variables followed a normal distribu-
tion or not, we used the Shapiro Wilks test.
For the comparison of quantitative variables in two
independent samples the Student’s t-test was used if the
variable followed a normal distribution and the Mann-
W h i t n e yU - t e s ti ns k e w e ds a m p l e s .I nm o r et h a nt w o
related samples, all of them were initially compared by
the Friedman-test. Then differences in values were tested
by pairwise comparisions using the Wilcoxon’ss i g n e d
rank test with Bonferroni’s correction. For the compari-
son of qualitative variables, we used chi-square or Fisher’s
exact test, as necessary.
For all comparisons, we considered statistical signifi-
cance to be a two-tailed alpha error probability of ≤ 5%
(P ≤ 0.05). Statistical analysis was performed by using
SPSS version 15 (SPSS Inc., Chicago, IL, USA).
Results
Clinical data
From February 2007 through June 2008, 43 consecutive
patients who met the inclusion criteria were randomly
assigned to receive a TPN with a daily supplement of
glutamine or not.
There were no statistically significant differences in
basal characteristics of both groups of patients treated
with and without glutamine (Table 1). Like some other
investigators we did not observe any adverse effect, stu-
died through the SOFA score, due to the use of these
doses of glutamine (Table 1).
T h e r ew e r ed e t e c t e d2 1p o s i t i v ec u l t u r e si nt h eg r o u p
of patients treated with glutamine and 32 positive cul-
tures in the control group (Table 2). The median of
ICU length of stay was similar in both groups and there
was a trend in the median of the hospital length of stay
not reaching statistically significance (Table 2).
Surface expression of TLR2 and TLR4
Monocytes from patients treated with glutamine
expressed the same TLR2 levels than monocytes from
control subjects before treatment (4.9 ± 3.5 rmfi vs.
Table 1 Baseline characteristics of patient population
TPN with Gl
(n = 23)
TPN without Gl
(n = 20)
P-value
Age (years) 34.2 ± 14.7 40.4 ± 15.2 0.18
Male/Female 19/4 18/2 0
Weight (Kg) 77.3 ± 11.3 81.9 ± 11.1 0.19
SAPS 35.8 ± 9.5 31.4 ± 13.5 0.27
APACHE 2 19.2 ± 3.2 15.1 ± 9.3 0.12
APACHE 3 48.3 ± 18.3 36.1 ± 18.3 0.06
ISS 31.4 ± 12.3 31.6 ± 12.6 0.96
Previous surgery 8 12 0.43
Previous shock 6 4 0.73
SOFA pretreatment 7 ± 3.7 7 ± 3 0.96
TPN beginning (days) 4.7 ± 3.1 4.3 ± 2.1 0.67
TPN duration 14 (8 to 19) 14.5 (8 to 23) 0.43
Norepinephrine 0.05 ± 0.1 0.2 ± 0.6 0.44
Pretreat. infection 11 9 0.98
SOFA postreatment 6.3 ± 3.4 6.8 ± 4.4 0.69
Data are presented as mean ± SD; number of patients or median (25th to
75th percentile).
SAPS, Simplified Acute Physiology Score; APACHE, Acute Physiology and
Chronic Health Evaluation; ISS, Injury Severity Score; Previous surgery, number
of patients that required surgery before randomization; Previous shock,
number of patients who presented a hemorrhagic shock before
randomization; SOFA pretreatment, Sequential Organ Failure Assessment
before treatment; TPN beginning, Number of days since hospital admission
before the patients were included in the study; TPN duration, Total duration
of the TPN in days; Norepinephrine, Medium dose of norepinephrine in μg×
Kg
-1 × minute
-1 during the five days of the treatment; Pretreat infection,
Number of patients with an infection before the randomization; SOFA
postreatment, Sequential Organ Failure Assessment after treatment (Day 6).
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Page 4 of 114.3 ± 1.9 rmfi, respectively; P = 0.9), at Day 6 (3.8 ±
2.3 rmfi vs. 4 ± 1.7 rmfi, respectively; P =0 . 7 )a n da t
D a y1 4( 4 . 1±2 . 1r f i mv s .4 . 6±1 . 9r m f i ,r e s p e c t i v e l y ;
P = 0.08) (Figure 1).
Concerning TLR4 expression, monocytes from
patients who received glutamine supplementation also
expressed similar levels of TLR4 than monocytes from
the control group before treatment (1.1 ± 1 rmfi vs 0.9
±0 . 1r m f ir e s p e c t i v e l y ;P = 0.9), at Day 6 (1.1 ± 1 rmfi
vs. 0.7 ± 0.4 rmfi respectively; P = 0.1) and at Day 14
(1.4 ± 1.9 rmfi vs. 1 ± 0.6 rmfi respectively; P =0 . 8 )
(Figure 2).
TLR functionality
Stimulation of monocytes with TLR specific agonists is
assumed as a marker for immune response in vivo [26].
We asked whether a glutamine dietary supplement may
affect the response of monocytes to different TLR ago-
nists. To this end, we measured the levels of TNFa,
IL-1b, IL-6 and IL-10 in supernatants of monocytes
challenged with either LPS (100 ng/mL), TLR4 agonist,
Pam3CSK4 (10 μg/mL) or zymosan (10 μg/mL), two
TLR2 agonists.
We present the results of the stimuli that induced the
strongest response. The levels of TNFa (Figure 3), IL-1b
(Figure 4), IL-6 (Figure 5) and IL-10 (Figure 6) produced
in response to LPS, Pam3CSK4 or zymosan were similar
in patients treated with and without glutamine pretreat-
ment, at Day 6 and at Day 14.
We also performed dose-response experiments using
lower concentrations of the same agonists and we only
found differences in the production of IL-10 after stimu-
lation with zymosan 0.1 μg/mL at baseline level (3.8 pg/
dL in the glutamine group vs 2 pg/dL in the control
Table 2 Complications and outcome of patients
TPN with
Gl (n = 23)
TPN without
Gl (n = 20)
P-value
Infections, n (%)
Respiratory infection 14 (61%) 14 (70%) 0.53
Urinary infection 1 (4%) 2 (10%) 0.6
Blood culture 1 (4%) 5 (25%) 0.08
Catheter infection 4 (17%) 6 (30%) 0.5
CSF infection 1 (4%) 1 (5%) 0.6
Wound infection 0 (0%) 4 (20%) 0.08
Pneumonia 11 (48%) 8 (40%) 0.6
Length of MV (days) 15.2 ± 8.2 18.9 ± 11.1 0.21
ICU length of stay (days) 21 (17 to 25) 21 (14 to 47) 0.47
Hospital length of stay
(days)
31 (19 to 42) 40 (24 to 80) 0.23
ICU mortality 4 (17%) 2 (10%) 0.7
Hospital mortality 0 (0%) 1 (5%) 1
Data are presented as mean±SD or median (25th to 75th percentile).
Respiratory infection, number of positive bronchial aspirate cultures during
ICU admission; Urinary infection, number of positive urine cultures during ICU
admission; Blood culture, number of positive blood cultures during ICU
admission; Catheter infection, number of positive blood cultures during ICU
admission; CSF infection, number of positive cultures of Cerebro Spinal Fluid;
Wound infection, number of positive cultures in the wound zone; Pneumonia,
number of patients who developed nosocomial pneumonia during ICU
admission; Length of MV, number of days of mechanical ventilation.
Figure 1 Expression of TLR2 in trauma patients treated with
and without glutamine. The expression of TLR2 was analyzed in
CD14 positive peripheral blood mononuclear cells. rmfi are shown
for 23 trauma patients treated with glutamine (black bars) and 20
trauma patients without glutamine and used as controls (white
bars). Samples were obtained at the beginning of the treatment
(Day 0); at the end of the treatment (Day 6) and at Day 14. Data are
given as mean ± SEM.
Figure 2 Expression of TLR4 in trauma patients treated with
and without glutamine. The expression of TLR4 was analyzed in
CD14 positive peripheral blood mononuclear cells. rmfi are shown
for 23 trauma patients treated with glutamine (black bars) and 20
trauma patients without glutamine and used as controls (white
bars). Samples were obtained at the beginning of the treatment
(Day 0); at the end of the treatment (Day 6) and at Day 14. Data are
given as mean ± SEM.
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Pam3CSK4 with 1 μg/mL stimulation (12.8 pg/dL in the
glutamine group vs 16.9 pg/dL in the control group).
For the rest of the 106 comparisons between both
groups and the different dose-response experiments, no
statistically significant differences were found.
We also asked whether glutamine dietary supplement
could alter the responses of monocytes for the three
agonists at the three time points studied (baseline, Day
6 and Day 14) for each patient receiving the treatment.
For this purpose and because there were more than two
related samples, all of them were initially compared by
the Friedman-test. Then differences in values were
tested by pairwise comparisions using the Wilcoxon’s
signed rank sum test with Bonferroni’s correction.
Within the group of patients who received glutamine we
f o u n da ni n c r e a s ei nt h ep r o d u c t i o no fT N F a after sti-
mulation with LPS 100 ng/mL (55.2 pg/dL at baseline;
63 pg/dL at Day 6; 146 pg/dL at Day 14), the produc-
tion of IL-10 after stimulation with LPS 100 ng/mL (45
pg/dL at baseline, 58 pg/dL at Day 5, 101 pg/dL at Day
14), the production of IL-6 after LPS 100 ng/mL stimu-
lation (5591 pg/dL at baseline; 6004 pg/dL at Day 6;
6065 pg/dL at Day 14) and the production of IL-1b
after LPS 100 ng/mL (249 pg/dL at baseline; 253 pg/dL
at Day 6; 379 pg/dL at Day 14). The rest of the stimula-
tions with Pam3CSK4 and zymosan at different doses
did not vary significantly over time in the group of
patients treated with glutamine.
However, we also found an increase in the cellular
responses to LPS over time in monocytes from the con-
trol group. Thus, levels of TNFa in supernatants of
LPS-treated monocytes were higher at Day 14 than at
Day 6 or baseline (96 pg/dL at baseline; 84 pg/dL at
Day 6, 218 pg/dL at Day 14). Likewise, levels of IL-10
after stimulation were also higher at Day 14 than at
baseline (45 pg/dL at baseline; 59 pg/dl at Day 6; 92 pg/
dL at Day 14). Like in the group of patients treated with
glutamine, the rest of stimulations with Pam3CSK4 and
zymosan at different doses did not affect significantly
over time.
Phagocytosis
Phagocytosis of pathogens also relies on the activation
of TLRs [28]. The phagocytic capability of both groups
studied before the beginning of the treatment, or at the
end of the treatment (Day 6) or at Day 14 was not sig-
nificantly different at any time point studied (Table 3).
Discussion
In this study we have shown that the TLR dysregulation
previously found in trauma ICU patients, reduced levels
of TLR2 and TLR4 expression, blunted response to TLR
agonists and reduced phagocytic ability of monocytes,
cannot be alleviated by glutamine dietary supplement.
One meta-analysis [29] reviewed seven studies with
326 cases that included a complication of infection, and
Figure 3 Concentration of TNFa in cell culture supernatants in
trauma patients treated with and without glutamine. TLR
functionality. Levels of TNFa analyzed by a bead array ELISA (CBA
Kit, BD Biosciences), in response to lipopolysaccharide (LPS-100 ng/
mL), Pam3CSK4 (PAM-10 pg/mL) and zymosan (ZYM-10 pg/mL) at
the beginning of the treatment (Figure 3A); at Day 6 (Figure 3B)
and at Day 14 (Figure 3C). Monocytes from trauma patients treated
with glutamine subjects (black bars, n = 23) and trauma patients
without glutamine (white bars, n = 20). Control bars are samples
production of cytokines by unstimulated monocytes. Data are given
as mean ± SEM.
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tions in the group of patients treated with glutamine:
RR 0.80; CI 95%; 0.64 to 1.00; P = 0.03. In addition
recent ESPEN guidelines recommend the use of
glutamine when TPN is indicated in ICU patients [30].
In our study, the treatment group also presented a
reduced incidence of infections and a reduced hospital
length of stay, although neither finding achieved statisti-
cal significance. In any case, our study was not designed
Figure 4 Concentration of IL1b in cell culture supernatants in
trauma patients treated with and without glutamine.T L R
functionality. Levels of IL1b analyzed by a bead array ELISA (CBA Kit, BD
Biosciences), in response to lipopolysaccharide (LPS-100 ng/ml),
Pam3CSK4 (PAM-10 pg/mL) and zymosan (ZYM-10 pg/mL) at the
beginning of the treatment (Figure 4A); at Day 6 (Figure 4B) and at
Day 14 (Figure 4C). Monocytes from trauma patients treated with
glutamine subjects (black bars, n = 23) and trauma patients without
glutamine (white bars, n = 20). Control bars are samples production of
cytokines by unstimulated monocytes. Data are given as mean ± SEM.
Figure 5 Concentration of IL6 in cell culture supernatants in
trauma patients treated with and without glutamine. TLR
functionality. Levels of Cytokines IL 6 analyzed by a bead array ELISA
(CBA Kit, BD Biosciences), in response to lipopolysaccharide (LPS-100
ng/ml), Pam3CSK4 (PAM-10 pg/mL) and zymosan (ZYM-10 pg/mL))
at the beginning of the treatment (Figure 5A); at Day 6 (Figure 5B)
and at Day 14 (Figure 5C). Monocytes from trauma patients treated
with glutamine subjects (black bars, n = 23) and trauma patients
without glutamine (white bars, n = 20). Control bars are samples
production of cytokines by unstimulated monocytes. Data are given
as mean ± SEM.
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reduction of the number of infections and/or hospital
length of stay, so this limitation precludes any conclu-
sion about efficacy.
The possible beneficial effects of glutamine on the
functionality of the innate immune system are poorly
characterized although these effects might be the under-
lying explanation of glutamine clinical effect on reducing
infectious complications. Taking into account that TLRs
play a central role in the activation of the innate system,
hence leading to the activation of different intracellular
signalling cascades involved in the activation of host
defence mechanisms, in this study we focused on the
effect of glutamine on the expression and functionality
of TLR2 and TLR4. A wealth of evidence indicates that
these TLRs recognize a plethora of pathogens. In fact, a
recent experimental study, treatment with enteral gluta-
mine was associated with down-regulation of TLR-4,
MyD88 and TRAF6 expression and concomitant decrease
in intestinal mucosal injury caused by LPS endotoxaemia
in rats [31]. These authors conclude that the positive
effect of glutamine on intestinal structure after LPS endo-
toxaemia may be considered as a mechanism via which
immunonutrition helps in the recovery of critically ill
patients.
As a population studied, we chose trauma patients
admitted to the ICU for various reasons. First, in a pre-
vious study [12] we did demonstrate that the TLR
expression and functionality are altered in monocytes
from traumatic patients, and that this alteration persists
during the first 14 days after hospital admission. Second,
several studies have demonstrated that a decrease or
even total lack of TLR expression correlate with greater
susceptibility to infection [32-34]. Altogether, trauma
patients make a good case study to test whether gluta-
mine dietary supplement may improve TLR-dependent
host defence mechanisms. On the other hand, it seems
reasonable to think that if we could improve TLR-
dependent host defence mechanisms by using a pharma-
conutrient such as glutamine the molecular mechanisms
to detect microorganisms might improve, resulting in a
reduced incidence of infectious complications. However,
the results of this study show that the TPN supplemen-
ted with glutamine does not change the expressions of
TLR2 or TLR4, the secretion of cytokines upon stimula-
tion with TLR agonists and the phagocytic capability.
Nevertheless critical care patients are heterogeneous and
it is possible that a hyperinflammatory response coexists
Figure 6 Concentration of IL10 in cell culture supernatants in
trauma patients treated with and without glutamine. TLR
functionality. Levels of Cytokines IL 10 analyzed by a bead array
ELISA (CBA Kit, BD Biosciences), in response to lipopolysaccharide
(LPS-100 ng/ml), Pam3CSK4 (PAM-10 pg/mL) and zymosan (ZYM-10
pg/mL)) at the beginning of the treatment (Figure 6A); at Day 6
(Figure 6B) and at Day 14 (Figure 6C). Monocytes from trauma
patients treated with glutamine subjects (black bars, n = 23) and
trauma patients without glutamine (white bars, n = 20). Control bars
are samples production of cytokines by unstimulated monocytes.
Data are given as mean ± SEM.
Table 3 Phagocytosis capability in patients treated with
and without glutamine
TPN with Gl
(n = 18)
TPN without Gl
(n = 14)
P-value
Pretreatment 61.3 ± 20.8 58.8 ± 24.6 0.8
Day 6 50.2 ± 22.8 51.8 ± 9 0.8
Day 14 56.5 ± 25.3 55.1 ± 21.5 0.9
Results were expressed as relative mean fluorescence intensity (rmfi). Data are
presented as mean ± SD.
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Page 8 of 11with a dysfunction in the immune system. As it has
been previously pointed out, TLR-4 expression is lower
in trauma patients than in healthy volunteers [12,13]
whereas in septic patients TLR expression increased
[35,36].
I ng e n e r a li ti sa s s u m e dt h a tt h el e v e l so fT L R sc o r -
relate with the cellular response upon stimulation with
specific agonists [26]. For example, macrophages over-
expressing TLRs, release higher amounts of inflamma-
tory mediators upon TLR engagement [37,38]. It is
also known that cells from trauma patients secrete
significantly less inflammatory cytokines than cells
from control subjects when LPS, a TLR4 agonist, is
used [12,13,39,40]. However, our data show that cells
from trauma patients treated with glutamine secreted
similar amounts of cytokines than cells from control
subjects upon stimulation with TLR2 and TLR4
agonists.
It is also known that phagocytosis is impaired in
monocytes from trauma patients [12]. Phagocytosis is an
ancient form of host defence which is dependent on sev-
eral signalling pathways including TLR-dependent sig-
nals [28]. Thus, it has been shown that activation of the
TLR signalling by bacteria regulates phagocytosis at
multiple steps, including internalization and phagosome
maturation [28]. Nevertheless, our findings, likewise pre-
vious ones in paediatric patients [41], show that gluta-
mine supplementation dose not increase the phagocytic
capacity.
Limitations of the study
It must be commented that there is controversy over the
surface expression of TLR2 and TLR4 by leukocytes
from traumatic patients. In our previous work [12], we
showed a reduced expression of both TLR2 and TLR4
in monocytes from those trauma patients who devel-
oped any infection. On the other hand, Adib-Conquy
et al. [13] reported a reduced expression of TLR4 in
severely injured patients early after trauma, whereas
TLR2 remained unchanged. In contrast, another study
[15] showed a down-regulation of the expression of
both TLR2 and TLR4, whereas Lendemans et al. [14]
observed a decrease of only TLR2 expression. Differ-
ences in the patients analyzed may account for these
conflicting results and we can not rigorously rule out
that technical issues such as the commercial source of
the antibodies used or the way the cells were fixed for
the flow cytometry experiments may also be responsible
for these conflicting results.
It also should be pointed out that an in vivo scenario
is quite complex and the final outcome of an infectious
process depends on the concerted action of several cells,
including epithelial, endothelial, neutrophils, macro-
phages and lymphocytes, and therefore, we cannot rule
out that glutamine may exert a positive effect on other
cell types or even at the level of cross-talk between cells
of the innate immune system. Studies are on going to
test these hypotheses.
In this study, we have analyzed different phenotypes of
circulating cells over time. It should be taken into con-
sideration that initial phenotypes may be compensated
after three to five days owing to the influx of new and
immature monocytes. In fact, this might be the explana-
tion underlying the increased response to different
agonists after six days. In any case, our data suggest that
glutamine dietary supplement may not affect cell turn-
over since the increased response was found in both
groups and, furthermore, no significant differences were
found between them.
Another limitation of the study is that we did not
measure plasma levels of free glutamine. Nevertheless it
must be said that previous studies have documented low
levels of glutamine in previously fit trauma patients, and
that the dose of glutamine employed in our study and
the length of treatment was enough to correct any defi-
ciency. It also should be noted that for the reported ana-
lysis of TLR expression and phagocytic ability, whole
blood samples, without subculturing cells, were used.
However, for the stimulation experiments using different
TLR agonists purified monocytes were challenged with
stimuli in tissue culture medium containing glutamine
which is commonly used to culture cells and perhaps
this glutamine present in the medium may mask differ-
ences between experimental groups. Nevertheless, the
impaired LPS response displayed by monocytes from
trauma patients reported by us and others [12-15] was
still found in both groups.
Conclusions
The results of this study in trauma ICU patients show
that TPN supplemented with glutamine does neither
improve the expression of TLR-2 or TLR-4 in circulat-
ing monocytes from peripheral blood, nor the func-
tionality of TLR-2 and TLR-4 studied by analyzing the
cytokine production after monocyte isolation and sti-
mulation or by studying the phagocytic capability.
Key messages
￿ The use of glutamine as a dietary supplement is
associated with a reduced risk of infection. It has
been postulated, though not formally proven yet,
that glutamine beneficial effect could be due to a
positive effect on the innate immune system.
￿ Given the importance of TLRs and TLRs-dependent
signalling in host defence against infections we
hypothesized that glutamine may increase the expres-
sion and/or functionality of TLRs, which in turn may
have beneficial effects to clear infections.
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Page 9 of 11￿ Nevertheless, the results of this study show that the
TPN supplemented with glutamine does neither
improve the expression of TLR-2 or TLR-4 in circu-
lating monocytes from peripheral blood, nor the func-
tionality of TLR-2 and TLR-4 studied by analyzing
the cytokine production after monocyte isolation and
stimulation or by studying the phagocytic capability.
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